Email this article Experience in the effective long-term use of adalimumab in the treatment of a patient with an early debut of juvenile idiopathic arthritis and uveitis
- Authors: Galstyan L.A.1, Zholobova E.S.1, Suchkova D.V.1, Chebysheva S.N.1, Meleshkina A.V.1
-
Affiliations:
- Meleshkina Sechenov First Moscow State Medical University (Sechenov University)
- Issue: No 2 (2020)
- Pages: 67-71
- Section: Articles
- URL: https://pediatria.orscience.ru/2658-6630/article/view/57120
- DOI: https://doi.org/10.26442/26586630.2020.2.200233
- ID: 57120
Cite item
Full Text
Abstract
A case of early debut of juvenile idiopathic arthritis in a 2-year-old patient associated with uveitis, refractory to methotrexate therapy, non-steroidal anti-inflammatory drugs, and topical glucocorticoids, is presented. The given clinical example demonstrates the high therapeutic efficacy of adalimumab. The duration of remission of the articular syndrome and uveitis was 5 years.
Full Text
About the authors
Lelia A. Galstyan
Meleshkina Sechenov First Moscow State Medical University (Sechenov University)Moscow, Russia
Elena S. Zholobova
Meleshkina Sechenov First Moscow State Medical University (Sechenov University)Moscow, Russia
Daria V. Suchkova
Meleshkina Sechenov First Moscow State Medical University (Sechenov University)Moscow, Russia
Svetlana N. Chebysheva
Meleshkina Sechenov First Moscow State Medical University (Sechenov University)
Email: svetamma@gmail.com
Moscow, Russia
Angelina V. Meleshkina
Meleshkina Sechenov First Moscow State Medical University (Sechenov University)Moscow, Russia
References
- Юношеский артрит. Клинические рекомендации. Союз педиатров России, 2016 г.
- Alberto Martini et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019; 46 (2): 190-7.
- Rigante D, Bosco A, Esposito S. The Etiology of Juvenile Idiopathic Arthritis. Clin Rev Allergy Immunol 2015; 49 (2): 253-61.
- Kasper M, Walscheid K, Laffer B et al. Phenotype of Innate Immune Cells in Uveitis Associated with Axial Spondyloarthritis- and Juvenile Idiopathic Arthritis-associated Uveitis. Ocular Immunol Inflammation 2020; p. 1-10.
- Галстян Л.А., Жолобова Е.С., Чебышева С.Н. и др. Увеит, ассоциированный с ювенильным идиопатическим артритом. Рос. вестн. перинатологии и педиатрии. 2019; 64 (2): 30-7.
- Игишева Л.Н., Притчина С.С., Быкова Ю.А., Аникеенко А.А. Ювенильные артриты: диагностика и лечение. Мать и дитя в Кузбассе. 2017; 1: 48-61.
- Hawkins MJ, Dick AD, Lee RJ et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthal Mol 2016; 61 (2): 197-210.
- Merida S, Palacios E, Navea A, Bosch-Morell F. New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci 2015; 16 (8): 18778-95.
- Алексеева Е.И., Бзарова ТМ., Валиева С.И. и др. Эффективность и безопасность человеческих моноклональных антител к ФНО-альфа у детей с ювенильным идиопатическим артритом при первичной и вторичной неэффективности других генно-инженерных биологических препаратов. Вопр. совр. педиатрии. 2012; 11 (4): 82-8.
- Silvestri E et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on BehHet’s syndrome. Inflammopharmacology 2020.
- Simonini G, Druce K, Cimaz R et al. Curent evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken) 2014; 66 (7): 1073-84. doi: 10.1002/acr222
- Kingsbury DJ, Bader-Meunier B, Patel G et al. Safety, effectiveness and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2to4years. Clin Rheumatol 2014. doi: 10.1007/s10067-014-2498-1
- Foeldvari I, Wierk A. Methotrexate is an effective treatment forchronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-5.
- Галстян Л.А. Сравнительная оценка эффективности и безопасности генно-инженерных биологических препаратов в лечении ювенильного идиопатического артрита с поражением глаз. Автореф. дис... канд. мед. наук. М., 2018.
- Gely C et al. Impact of pain due to subcutaneous administration of a biological drug. Abstract N032 presented at the 13th Congress of ECCO -European Crohn’s and Colitis Organisation
- Инструкция по медицинскому применению лекарственного препарата Хумира® 100 мг/мл. http://grls.rosminzdrav.ru/grls.aspx. Доступ от 21.05.2020
- Инструкция по медицинскому применению лекарственного препарата Хумира® 40 мг/0,8 мл. http://grls.rosminzdrav.ru/grls.aspx. Доступ от 21.05.2020
- Nash P et al. Randomized Crossover Comparison of Injection Site Pain With 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients With Rheumatoid Arthritis. Rheumatol Ther 2016; 3 (2): 257-70.
Supplementary files
